
After Big Pharma flops, Chong Kun Dang reopens CETP race with US trial
After Eli Lilly, Pfizer, and MSD (Merck & Co. in the U.S. and Canada) walked away from CETP inhibition, Korean pharma Chong Kun Dang is stepping in with a bet on dyslipidemia, a condition marked by abnormal cholesterol and triglyceride levels. The …